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Body Fluid Composition in Liver Disease
Approximately 2 thirds of the total body water is nor-
mally contained in the intracellular compartment while
the remaining 1 third is distributed in the intravascu-
lar and intercellular space. At any 1 point within a car-
diac cycle, most of the total blood volume is found 
in the systemic veins with only 10% in the splanchnic
circulation (Figure 1).1,2
The distribution of total body fluid is altered by liver
disease. Sodium and water are retained by the kidneys
and this increases the amount of total body fluid. Fluid
shifts into the intracellular compartment, which expands
to accommodate the increased volume.3 In disease, this
compartment commonly holds 3 quarters or more of
the total body water.4 Protein-rich fluid moves into the
body cavities as disease worsens. This causes ascites and
pleural or pericardial effusion.5 As disease progresses,
total blood volume increases but the relative amount
of blood in the systemic circulation falls. Rather, blood
moves into splanchnic (gut) circulation as it expands due
to portal hypertension (Figure 2). Tissue oxygenation
is therefore impaired.
These changes are initiated by the development of
portal hypertension. Portal hypertension causes vasodi-
latation and new blood vessel formation in the splanch-
nic circulation.6 An increase in the number of small slow
transit blood vessels in the gut increases the capaci-
tance of the splanchnic circulation. Blood enters this
low resistance circulation and becomes unavailable to
the systemic circulation.2 The resulting fall in arterial
blood volume activates the arterial baroreceptors. Tonic
impulses to the central nervous system from arterial
baroreceptors normally inhibit the sympathetic nervous
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Figure 1. The normal distribution of blood in body compartments.
system and the nonosmotic secretion of arginine vaso-
pressin.7 A fall in arterial pressure causes a loss of arterial
baroreceptor activity. In turn, this triggers an increase
in sympathetic nervous system activity and arginine
vasopressin is secreted. The resulting increase in renal
adrenergic activity reduces the amount of water and
sodium delivered to the collecting duct of the kidneys.
The latter causes the kidney to secrete renin, arginine
vasopressin and natriuretic peptide (Figure 3).
Normally, this neurohormonal pathway restores
circulating blood volume. However, portal hyperten-
sion is progressive and therefore the capacity of the
splanchnic circulation increases with under-filling of the
arterial circulation. This continues to drive the neuro-
hormonal response that causes the retention of sodium
water and other solutes even though total body water
and sodium is increased. The reduced solute delivery to
the kidney is such a strong stimulus that the sodium-
retaining effects of aldosterone predominate over the
diuretic effects of natriuretic peptide. Total body fluid
homeostasis can only be restored by the effective
treatment of portal hypertension.6
Heart Disease in Cirrhosis
Physicians previously thought that heart disease was
rare in patients with cirrhosis.8 They hypothesized that
better lipid profiles, reduced blood clot formation and
lower blood pressures in cirrhotic patients reduced
cardiac complications. Further, few perioperative car-
diovascular complications were observed in the early
history of transplantation. However, postoperative mor-
tality at that time was primarily due to operative compli-
cations and poor donor graft function. Better surgical
technique and donor organ management significantly
improved overall patient outcome. As long-term patient
survival improved, cardiac complications emerged as
a more common cause of early morbidly and mortality.
Recent studies report radiographic evidence of pul-
monary edema with hypoxemia and overt congestive
heart failure in as many as 56% and 5.6% of all periop-
erative transplant recipients, respectively.9,10 It is also
remarkable that hemodynamically significant cardiac
arrhythmias are reported in up to 27% of transplant
recipients following surgery.10
Ischemic heart disease
Even though cirrhotic patients have more cardiovas-
cular complications than the general public, the pre-
operative diagnosis of cardiac disease is still difficult.
Patients with advanced and end-stage liver disease usu-
ally have poor exercise capacity. Consequently, they
may not experience common symptoms that are usually
provoked by exercise such as chest pain or shortness of
breath. Further, it may be impossible to determine if
some symptoms such as shortness of breath are caused
by cardiac or liver disease. The exact prevalence of
angiographically proven critical coronary artery ste-
nosis (> 50%) in liver transplant candidates is unknown.
However, the evidence suggests that coronary artery
disease (CAD) is more prevalent in transplant can-
didates. Generally, investigators report that at least 
1 critical coronary artery lesion occurs in 5–26% of all
liver transplant candidates who are asymptomatic.11–14
Of these patients, up to 50% with significant CAD
will die perioperatively from cardiac complications.12
This is substantially greater than the 1-year mortality
rate (10%) for all liver transplant recipients15 or the
mortality rate from cardiac complications for other
study populations.16,17 The latter makes the identifi-
cation of CAD prior to transplantation a precedent. 
A previous history or classic symptoms of CAD place
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Figure 2. The distribution of blood volume in patients with portal
hypertension.
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Figure 3. The neurohormonal reflex that causes an increase in
renal water and solute absorption.
patients in well-tested protocols that direct further
evaluation.18,19 However, the challenge remains in
identifying those patients who are asymptomatic but
have significant CAD.
Cardiomyopathy
The prevalence of cardiomyopathy is greater in patients
with end-stage liver disease than in the general popu-
lation.20,21 Conditions such as hepatitis C can cause
immune-mediated myocarditis and fibrosis resulting in
restrictive cardiomyopathy.21 Hemochromatosis and
amyloidosis also cause restrictive cardiomyopathy due
to the infiltration of iron and protein respectively.22,23
Findings similar to dilated cardiomyopathy are also
commonly reported from routine echocardiographic
screening of transplant candidates.20 Further, an in-
creased reporting of hypertrophic cardiomyopathy in
transplant candidates suggests that this disorder may
also be more prevalent in cirrhotic patients.24,25
Cirrhotic cardiomyopathy
Some cirrhotic patients have obvious feature of car-
diomyopathy. However, most have a normal or even
supernormal ejection fraction judged by echocardiog-
raphy. Thus, physicians often assume that cardiac func-
tion is normal in these patients. However, further
investigation has uncovered multiple problems in car-
diac performance that place patients at risk of heart
failure. Early cardiac decompensation is often missed
because the cardiac workload is reduced by peripheral
vasodilatation caused by liver failure.26 Thus, cirrhotic
patients are dismissed as having normal heart function.
However, when these patients are subject to physiologic
or pharmacologic stress, they develop clinical signs of
suboptimal perfusion including renal failure and aci-
dosis. Investigators have concluded that exercise uncov-
ers an intrinsic defect in myocardial function that
predisposes to heart failure.27,28
Most patients with liver disease have subtle defects
in myocardial function that are not apparent on cur-
sory examination. Defects in both systolic and dias-
tolic function only become obvious with physiologic
stress such as liver transplantation.29 This condition is
termed “cirrhotic cardiomyopathy” and, although the
clinical presentation can be variable, all patients have
4 common features. These are: (1) baseline increased
cardiac output; (2) attenuated systolic contraction and
diastolic relaxation; (3) electrophysiologic abnormali-
ties including repolarization change; and (4) a reduced
response of the heart to direct beta stimulation 
(β-incompetence).30 These changes occur in the ab-
sence of overt congestive ventricular failure and with
only modest changes such as mild chamber dilatation.
At rest, systolic function appears to be normal in
most patients with liver disease. However, the mechan-
ics of systolic contraction are commonly disturbed. This
is shown by examination of the systolic time interval.
The length of systole remains constant, but left ven-
tricular ejection period takes up a larger percentage of
the time interval. This in turn shortens the pre-ejection
period.31 In contrast to changes in diastole, systolic dys-
function usually only becomes evident during exercise.
Ejection fraction does not increase as expected under
conditions of stress. An increase in filling pressures
does not increase ejection fraction as expected and
the Frank Starling curve flattens. As liver disease pro-
gresses, systolic function can be insufficient to meet
tissue oxygen demands even at rest.32 The impaired
systolic response to stress is etiologic in the increased
incidence of pulmonary edema and congestive heart
failure following procedures that abruptly increase
blood flow to the heart.
Early histologic changes in cirrhotic hearts include
myocardial hypertrophy, interstitial and cellular edema,
and signs of cellular injury.33 This causes global thicken-
ing of the left ventricle with the septum affected more
than the free wall.29 Overall, these effects are more pro-
nounced in patients with ascites compared to those
without. As wall thickness increases, so does the degree
of diastolic dysfunction. Impaired diastolic relaxation
prolongs isovolumetric relaxation and also produces a
steep compliance curve where the ventricular pressure is
greater than normal for any given end diastolic volume.
The left atrium dilates in response to the higher imped-
ance to left ventricular filling. When patients are exposed
to acute changes in circulation that rapidly increase fill-
ing pressure, they are at risk of developing congestive
heart failure. This accounts for the high incidence of
congestive heart failure after procedures such as trans-
jugular intrahepatic shunts and liver transplantation.34
In fact, diastolic disturbance is such a consistent feature
of cirrhotic cardiomyopathy that many investigators
suggest that some degree of diastolic dysfunction is
present in all patients with liver disease.
Patients with liver disease exhibit 3 common car-
diac electrophysiologic disturbances in cardiac func-
tion. These include: (1) electromechanical dissociation;
(2) prolongation of ventricular polarization (the QT
interval); and (3) chronotropic incompetence.33 The
time period between electrical and mechanical systole
is longer in patients with cirrhosis.35 If the conduct-
ing system is still partially depolarized when the next
action potential arrives, electrical depolarization cannot
capture all the mechanical activity of the myocardium.
Once electromechanical dissociation becomes se-
vere, it prolongs the time required for repolarization
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(QT interval). Prolongation and variability in the QT
interval can affect cardiac rhythm and cause serious dis-
turbances including ventricular fibrillation. The severity
of electromechanical dissociation is clearly related to
the severity of liver disease. This is shown by the fact
that the length of the QT interval correlates directly
with the Child-Pugh score.31 While patients with con-
genital prolonged QT appear to have defects in the
sodium receptors that regulate electrical gating, the
potassium gates of the conducting system are primarily
affected in patients with liver disease.36
Chronotropic incompetence is the inability of the
sinus node to increase heart rate in response to phys-
ical or metabolic stress. The conducting system is
dominated by the parasympathetic system and there 
is a downregulation in the number and sensitivity of
β-receptors. Chronotropic incompetence is an inde-
pendent predictor of mortality in patients with cardiac
disease. But it is not known if it also predicts mortal-
ity in patients with liver disease. However, failure to
adapt heart rate to physiologic demand has important
consequences in patients with liver disease. Because
contractility is depressed, heart rate becomes a major
determinant of cardiac output in patients with liver
disease. Chronotropic incompetence explains the fail-
ure to reach target heart rates during dobutamine stress
testing.
Conclusion
Cardiac disease is a common complication of liver dis-
ease that reduces post-transplant survival. Ischemic
heart disease and cardiomyopathy occur more com-
monly in liver transplant candidates than most other
surgical patients. There is still considerable debate on
whether it is cost-effective to screen all transplant can-
didates for the presence of coronary and structural
heart disease. The unusually high perioperative mor-
tality in transplant patients who do have CAD incurs a
significant price in terms of cost and the preventable
loss of human organs. These considerations support a
systematic evaluation of all liver transplant candidates.
No single test has 100% predictive value. Therefore,
diagnostic protocols must account for the variation in
prevalence that occurs in subsets of transplant candi-
dates and the limitation of each type of test.
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